Search

Your search keyword '"Lipitor (Medication) -- Evaluation"' showing total 2 results
Start Over Descriptor "Lipitor (Medication) -- Evaluation" Journal pharma marketletter
2 results on '"Lipitor (Medication) -- Evaluation"'

1. Vytorin beats Lipitor in high-risk patients

Subjects
Anticholesteremic agents -- Evaluation, Pharmaceuticals and cosmetics industries, Vytorin (Medication) -- Evaluation, Lipitor (Medication) -- Evaluation
Abstract

Data presented at the American Cardiology Association's annual meeting held in Orlando, USA, revealed that Merck & Co and Schering-Plough's Vytorin (ezetimibe) appears to be more effective in reducing low-density [...]

Published
2005

2. AstraZeneca's Crestor is superior to Lipitor in reducing CVD risk factors in diabetics

Subjects
AstraZeneca PLC -- Product development, Diabetes -- Risk factors, Cardiovascular diseases -- Risk factors, Anticholesteremic agents -- Evaluation, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Crestor (Medication) -- Evaluation, Lipitor (Medication) -- Evaluation
Abstract

New findings presented at the European Atherosclerosis Society Congress in Seville, Spain, show that AstraZeneca's Crestor (rosuvastatin) is more effective in lowering low-density lipoprotein cholesterol in patients with type 2 [...]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results